FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 10:28:01 17/05/2024 pm IST | ||
| 4.34 EUR / 4.36 EUR | -7.25% |
|
| Current month | -68.20% | ||
| 1 month | -68.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 4.4 | -6.18% |
| 16/24/16 | 4.69 | -7.68% |
| 15/24/15 | 5.08 | -17.40% |
| 14/24/14 | 6.15 | +0.33% |
| 13/24/13 | 6.13 | -16.14% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 10:19 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J26 |
| ISIN | DE000JK2J260 |
| Date issued | 23/02/2024 |
| Strike | 489.6 $ |
| Maturity | Unlimited |
| Parity | 10.43 : 1 |
| Emission price | 10.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.21 € |
|---|---|
| Lowest since issue | 4.4 € |
| Spread | 0.02 € |
| Spread % | 0.45% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- Certificat
